Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024

Influenza Other Respir Viruses. 2024 Aug;18(8):e13360. doi: 10.1111/irv.13360.

Abstract

We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.

Keywords: COVID‐19 XBB.1.5 vaccine; Europe; SARS‐CoV‐2 hospitalisation; vaccine effectiveness.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • COVID-19 Vaccines* / administration & dosage
  • COVID-19 Vaccines* / immunology
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Case-Control Studies
  • Europe / epidemiology
  • Female
  • Hospitalization* / statistics & numerical data
  • Humans
  • Male
  • Middle Aged
  • SARS-CoV-2* / immunology
  • Vaccination* / statistics & numerical data
  • Vaccine Efficacy* / statistics & numerical data
  • Young Adult

Substances

  • COVID-19 Vaccines